Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 25, 2024 16:05 ET | Travere Therapeutics, Inc.
Travere Therapeutics has entered into an exclusive licensing agreement with Renalys Pharma to bring sparsentan to patients in Japan.